Skip to main content

 

ACR Updated Guideline on Vaccinations for Rheumatic Patients

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

Approach to ILD in Myositis Syndromes

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

Rheumatic Causes for Fever of Unknown Origin

Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.

Early, Aggressive and Seropositive (7.22.2022)

Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.

Fever Pitch (7.15.2022)

Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on RheumNow.com

EULAR 2022 – Day 4 Report

Bags are packed, ready to go, but wait there’s more abstracts to show.

The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 

EULAR 2022 – Day 3 Report

By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around (lots of sneaker mileage)!  And congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, twe

EULAR 2022 – Day 2 Report

A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon.  The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.

Babies! Safety and Outcomes Data on Pregnancies

EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years.

EULAR 2022 Featured Industry Abstracts

Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.

Recommendations – Good & Bad (5.27.2022)

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?

Methotrexate Monitoring (5.13.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.

Social

FDA Safety Warning: denosumab now has a Boxed Warning for risk of severe hypocalcemia in CKD pts taking Prolia (usually seen 2-10 wks post injx). Pts may or may not be symptomatic. CKD pts should have Ca and Creatinine monitored. https://t.co/UMYxjWz9n4 https://t.co/AG5wzBrY1Y
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Dr. Gabalawy: "How do you know what disease patients will develop in this preclinical autoimmunity state?" @drdavidkarp "it's like when weeds pop up in a garden, it's random ...if ACPA Ab pops up, you might have RA, if it's dsDNA, maybe lupus." #RNL2024 @RheumNow https://t.co/JmDtaTt3sU
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 10 months ago
Treatment of SLE. EULAR guidelines via @Kahlenberglab @RheumNow #RNL2024 https://t.co/a5lWfRLuh3
Richard Conway @RichardPAConway ( View Tweet )
1 year 10 months ago
Lupus has many flavors. If we are better able to sort them, we might be more better at finding effective treatments. @rheumnow #RNL2024 @DrDavidKarp https://t.co/rklqnA8Ur6
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 10 months ago
Face and neck vitiligo also responds to topical ruxolitinib. Dr. Strober #RNL2024 @RheumNow https://t.co/6N6A3Yq7RE
Dr. Rachel Tate @uptoTate ( View Tweet )
1 year 10 months ago
Experience the Future of Rheumatology at RheumNow Live 2024, just two weeks away! Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights. https://t.co/bbnb97MOHO https://t.co/QXO34ZmP2i
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Experience the Future of Rheumatology at RheumNow Live 2024, just three weeks away! Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights. https://t.co/HN8ErCpSMb https://t.co/kCYD7Hbhxx
Dr. John Cush @RheumNow ( View Tweet )
1 year 11 months ago
Early bird pricing has been extended! Register today! https://t.co/wuvDqE0Qe6 https://t.co/8XXcQUBK6G https://t.co/ISRYMVdRfr
Dr. John Cush @RheumNow ( View Tweet )
2 years ago
Telitacicept (BlyS/APRIL inhibitor) ph3 in RA wholly in China, after SLE approval there (SLE trial now w global sites) Efficacy okay, no better than other b/tsDMARDs What's the hook here, in a crowded RA market incl biosimilars? Safety does look good though #ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A
David Liew @drdavidliew ( View Tweet )
2 years 1 month ago
×